Shares of UnitedHealth Group (NYSE:UNH | UNH Price Prediction) are up 4% at midday Tuesday, trading near $368, while Humana (NYSE:HUM) stock is also up 4% to $233. Both managed care names are extending one of the most aggressive sector rebounds of 2026.
UnitedHealth stock is up 36% from $270.59 at the end of March, while Humana stock is up 34% from $173.39 over the same time span. That’s a sharp reversal after a brutal late-2025 run that left both names deeply oversold.
The leader is clear. UnitedHealth is winning the April race on price, fundamentals, and year to date (YTD) performance, with UNH stock up 12% YTD versus Humana’s -9%. So, what’s going on with these two healthcare giants?
Earnings Beat and Raise Power UnitedHealth’s Run
UnitedHealth’s April 21 Q1 2026 earnings report was a major catalyst. Adjusted EPS came in at $7.23 versus the $6.57 consensus, while revenue of $111.72 billion topped the $109.57 billion estimate.
The standout metric was the medical cost ratio, which improved to 84% from 85% a year earlier. UnitedHealth’s management raised its 2026 adjusted EPS outlook to more than $18.25, up from the prior $17.75 bar, and maintained revenue guidance of greater than $439 billion.
UnitedHealth CEO Stephen Hemsley said the company is “continuing to help simplify and modernize health care for the people and care providers we serve, bringing greater value, affordability, transparency and connectivity.” Reddit sentiment on the report spiked to a bullish 74 score on r/WallStreetBets.
Humana’s Rally Reflects Stabilization After Steep Drawdown
Humana stock’s April bounce is real, but it’s a recovery from lows set around the Q4 2025 earnings report on February 11. That report showed FY2025 adjusted EPS of $17.14, while management guided FY2026 to at least $9, a sharp step down driven by Star Ratings headwinds.
The bullish narrative for HUM stock centers on individual Medicare Advantage growth of roughly 25% in 2026, with January membership up about 1,030,700. Humana CEO Jim Rechtin said the company feels “good about our consumer-focused strategy and our individual Medicare Advantage membership growth in 2026.”
The risk for Humana is concentration. The company’s heavy Medicare Advantage tilt leaves HUM stock more exposed to Medicare Advantage rate decisions and Star Ratings volatility than UnitedHealth’s diversified book.
Why UnitedHealth Is Winning
The diversification gap is the cleanest explanation. UnitedHealth’s Optum unit, spanning pharmacy benefits, healthcare services, and data, delivers earnings streams that don’t swing with Medicare Advantage rate notices. UnitedHealthcare’s operating margin still expanded to 7% with segment operating earnings of $5.69 billion.
Sector tailwinds are also lifting the group. Softer Q1 2026 hospital volumes from peers like HCA imply lower utilization, which feeds directly into lower medical costs paid by insurers. The recent finalization of an average 2% rate increase for 2027 Medicare Advantage payments has added fuel for both UnitedHealth and Humana.
For deeper context on the snapback, see our recent coverage of healthcare stocks rallying as managed care rebounds. The broader payer group is participating, yet UNH stock and HUM stock are leading the move.
What to Watch Next
Humana reports its Q1 2026 results on April 29, and Polymarket traders are pricing a 76% probability that the company beats. Management has telegraphed that Q1 will run 110% to 115% of full-year adjusted earnings, so the HUM headline could look strong even as the full-year reset stays in place.
Keep an eye on medical cost trend commentary from both teams. If UNH’s roughly 36% April surge holds and Humana confirms its Medicare Advantage membership story tomorrow, the managed care recovery trade has room to extend.
The bear case for UNH and HUM still matters. Regulatory risk on Medicare Advantage rates, drug pricing reform, and any reacceleration in cost trends could quickly cool a rally that has already run sharply in a month, leaving prudent investors with reason to size positions carefully.
Top Gaining Stocks
Top Losing Stocks